Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting

Investors

Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP’s strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.

News

07.18.2023

The Medicine Maker — Laser Focus: Sitting Down With…Theresa Heah, CEO, Intergalactic Therapeutics, Cambridge, Massachusetts

Read On

06.28.2023

Outsourcing-Pharma — Women in Science: Dr. Theresa Heah and her mission to ‘open new frontiers’ in medicine

Read On

06.27.2023

Ophthalmology Times — Intergalactic Therapeutics announces positive results for Its non-viral gene therapy platform in ABCA4 retinopathies in non-human primates

Read On

06.27.2023

Intergalactic Therapeutics Announces Positive Results for Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies in Non-Human Primates

Read On

06.14.2023

Nature Biotechnology — Why gene therapies must go virus-free

Read On

05.16.2023

Intergalactic Therapeutics to Host Virtual KOL Investor Event on May 23, 2023

Read On

05.11.2023